1
by Fu, Rongwei, Holmer, Haley K.
Published 2015
Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services
... and Quality that included at least one meta-analysis for continuous outcomes using mean difference. Data were...

2
by Fu, Rongwei, Holmer, Haley K.
Published 2015
Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services
... and Quality that included at least one meta-analysis for continuous outcomes using mean difference. Data were...

3
by McDonagh, Marian S.
Published 2010
Oregon Health & Science University
... and agranulocytosis, differences among the drugs in other serious harms have not been clearly shown. Evidence on long...

4
by McDonagh, Marian S.
Published 2010
Oregon Health & Science University
... and agranulocytosis, differences among the drugs in other serious harms have not been clearly shown. Evidence on long...

5
by McDonagh, Marian S.
Published 2011
Oregon Health & Science University
..., but the difference was influenced by dose and resolved after 2 years of treatment. Atomoxetine caused similar...

6
by McDonagh, Marian S.
Published 2011
Oregon Health & Science University
..., but the difference was influenced by dose and resolved after 2 years of treatment. Atomoxetine caused similar...

7
by Smith, M. E. Beth
Published 2011
Oregon Health & Science University
... small sample size that was underpowered to detect a difference. Compared with placebo, duloxetine...

8
by Smith, M. E. Beth
Published 2011
Oregon Health & Science University
... small sample size that was underpowered to detect a difference. Compared with placebo, duloxetine...

9
by Carson, Susan
Published 2011
Oregon Health & Science University
...-acting opioids, the evidence was insufficient to determine if there are differences among long-acting...

10
by Carson, Susan
Published 2011
Oregon Health & Science University
...-acting opioids, the evidence was insufficient to determine if there are differences among long-acting...

11
by Helfand, Mark
Published 2008
Department of Veterans Affairs, Health Services Research & Development Service
..., how do differences in timing and frequency of assessment, severity of pain, and follow-up of pain...

12
by Helfand, Mark
Published 2008
Department of Veterans Affairs, Health Services Research & Development Service
..., how do differences in timing and frequency of assessment, severity of pain, and follow-up of pain...

13
by Chou, Roger
Published 2007
Oregon Health & Science University
... if there are clinically significant differences between dual therapy with pegylated interferon-alfa 2a versus pegylated...

14
by Chou, Roger
Published 2007
Oregon Health & Science University
... if there are clinically significant differences between dual therapy with pegylated interferon-alfa 2a versus pegylated...

15
by Gartlehner, Gerald
Published 2011
Oregon Health & Science University
... AND CONCLUSIONS: Overall, we found no substantial differences in comparative efficacy and effectiveness of second...

16
by Gartlehner, Gerald
Published 2011
Oregon Health & Science University
... AND CONCLUSIONS: Overall, we found no substantial differences in comparative efficacy and effectiveness of second...

17
by Chou, Roger
Published 2011
Agency for Healthcare Research and Quality
...There were no clear differences between glucosamine or chondroitin and oral NSAIDs for pain...

18
by Chou, Roger
Published 2011
Agency for Healthcare Research and Quality
...There were no clear differences between glucosamine or chondroitin and oral NSAIDs for pain...

20
by Lee, Nancy J.
Published 2008
Oregon Health & Science University
... whether differences in efficacy and effectiveness exist between the 2 topical agents. The purpose...